Why the study?
Does renal denervation improve outcomes or surrogates in patients with chronic heart failure?
Does renal denervation improve outcomes or surrogates in patients with chronic heart failure?
This review outlines the pathophysiological rationale for investigating renal denervation as a potential therapeutic strategy in chronic heart failure.
Answers are grounded in this paper and cite their sources.
Does not support routine renal denervation use in heart failure; leaves open efficacy pending randomized outcome trials.
The activation of the sympathetic nervous system is associated with cardiovascular hospitalizations and death in heart failure. Renal denervation has been shown to effectively reduce sympathetic overdrive in certain patients with uncontrolled hypertension. Pilot trials investigating renal denervation as a potential treatment approach for heart failure were initiated. Heart failure comorbidities like obstructive sleep apnea, metabolic syndrome and arrhythmias could also be targets for renal denervation, because these occurrences are also mediated by the activation of the sympathetic nervous system. Therefore, renal denervation in heart failure is worthy of further investigation, although its effectiveness still has to be proven. Herein, we describe the pathophysiological rationale and the effect of renal denervation on surrogates of the heart failure syndrome.
No takes yet. Share an insight, caveat, or question.
Böhm et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: